Table 1 Clinical characteristic of TCGA and PUTH
TCGA | PUTH | |
|---|---|---|
Age | ||
≤ 55 | 161 (39.2%) | 50 (55.6%) |
> 55 | 250 (60.8%) | 40 (44.4%) |
Stage | ||
I | 16 (3.9%) | 3 (3.3%) |
II | 22 (5.4%) | 4 (4.4%) |
III | 309 (75.7%) | 52 (57.8%) |
IV | 61 (15.0%) | 31 (34.4%) |
Grade | ||
G1 | 3 (0.7%) | 1 (1.1%) |
G2 | 51 (12.5%) | 1 (1.1%) |
G3 | 344 (84.3%) | 88 (97.8%) |
GB | 2 (0.5%) | |
GX | 8 (2.0%) | |
Prior_treatment | ||
No | 411 (100%) | 90 (100%) |
Yes | 0 | 0 |
Primary_site | ||
Ovary | 411 (100%) | 90 (100%) |
Other | 0 | 0 |
Pathological type | ||
Serous cystadenocarcinoma | 411 (100%) | 90 (100%) |
Other | 0 | 0 |